KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Free Cash Flow: 2009-2024

Historic Free Cash Flow for Nektar Therapeutics (NKTR) over the last 16 years, with Dec 2024 value amounting to -$177.2 million.

  • Nektar Therapeutics' Free Cash Flow fell 9.59% to -$48.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$190.4 million, marking a year-over-year decrease of 7.05%. This contributed to the annual value of -$177.2 million for FY2024, which is 8.42% up from last year.
  • As of FY2024, Nektar Therapeutics' Free Cash Flow stood at -$177.2 million, which was up 8.42% from -$193.5 million recorded in FY2023.
  • Nektar Therapeutics' Free Cash Flow's 5-year high stood at -$177.2 million during FY2024, with a 5-year trough of -$427.6 million in FY2021.
  • Moreover, its 3-year median value for Free Cash Flow was -$193.5 million (2023), whereas its average is -$226.8 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first slumped by 33.41% in 2021, then soared by 37.53% in 2023.
  • Yearly analysis of 5 years shows Nektar Therapeutics' Free Cash Flow stood at -$320.5 million in 2020, then slumped by 33.41% to -$427.6 million in 2021, then rose by 27.58% to -$309.7 million in 2022, then surged by 37.53% to -$193.5 million in 2023, then rose by 8.42% to -$177.2 million in 2024.